Program Profile: Intensive Judicial Supervision (IJS) in Parramatta Drug Court (Australia)

This intervention was designed to increase the level of judicial oversight on participants convicted of misdemeanor crimes in the Parramatta Drug Court program. The program was rated Promising. Results indicated that participants under intensive judicial supervision had lower rates of positive drug tests, compared with the comparison group. This difference was statistically significant. However, there were no statistically significant differences in sanctions, program progression or termination.

A Promising rating implies that implementing the program may result in the intended outcome(s).

A Promising rating implies that implementing the program may result in the intended outcome(s).

Program Goals/Target Population

Intensive Judicial Supervision (IJS) was implemented in Parramatta Drug Court in Western Sydney, Australia, as a replication of the Delaware Drug Court program (Marlowe et al. 2003). The IJS program was designed to increase the level of judicial oversight over those convicted of misdemeanor crimes. The goals are to reduce recidivism and drug use.

Program Components

All Parramatta Drug Court participants receive identical drug treatment programs: the only differences are in their respective judicial supervision requirements. Participants in the Parramatta Drug Court program are required to pass through three phases of treatment (initiation, consolidation, and reintegration) before being eligible to graduate from the program. Participants are considered to have started the program when their case is held over for initial sentencing. This involves remanding participants in custody for a 2-week period of detoxification and setting a court date to adjudicate the initial offense (for which they had previously received a suspended prison sentence).

Participants are required to submit frequent supervised urine tests and report back to the court regularly during each phase. During Phase 1 (which usually lasts a minimum of 3 months), supervised urine testing is scheduled three times per week, while urine testing is scheduled twice weekly during Phases 2 and 3. During Phase 1, participants are required to report back to the court once each week, once every 2 weeks during Phase 2, and monthly during Phase 3. Participants supervised under the IJS intervention, however, are required to appear in court twice per week (instead of just once per week) during Phase 1 for a minimum of 4 months (instead of 3 months). During Phase 2, their supervision is gradually reduced to weekly report-back court visits, and then to visits every 2 weeks by Phase 3 if they show sustained abstinence. The urine testing schedule remains the same.  

Individual treatment plans for Parramatta Drug Court participants are provided by external treatment providers located within local health districts in the state of New South Wales. Participants also attend group sessions based on cognitive-behavioral principles, as needed. The program uses pharmacotherapy as a treatment for heroin dependence, primarily methadone or buprenorphine maintenance therapy.

The drug court program uses a flexible sanctioning and reward system. Failure to attend counseling sessions or court is deemed noncompliance. With regard to sanctioning, participants can accumulate up to 14 sanction days before being remanded to serve their sanctions in custody. Continued substance use results in a period of confinement in prison. For the reward systems, participants may have sanctions waived for sustained periods of abstinence. Nondisclosed instances of drug use incur more severe sanctions than admitted uses.

The drug court program is intended to run for at least 12 months, but the actual length of participation varies depending on the length of time participants spend in initial sentences and on their performance in the program.

Study

Jones (2013) conducted a nonblinded randomized controlled trial to examine the impact of the intensive judicial supervision (IJS) program on drug use, sanctions, program progression, and program termination of drug court clients in the Parramatta Drug Court in Sydney, Australia. All drug court program participants received identical drug treatment; the differences were in their respective judicial supervision requirements and the length of time they were scheduled to remain in the first phase of the program. Participants were either randomly assigned to the IJS group or the supervision as usual (SAU) control group. Those in the SAU group were required to appear in court once per week during Phase 1 (for a minimum of 3 months), once every 2 weeks during Phase 2 (for a minimum of 3 months), and once every 4 weeks thereafter. Those in the IJS group were required to appear in court twice per week (instead of once per week) during Phase 1 for a minimum of 4 months (instead of 3 months). During Phase 2, supervision was gradually reduced to weekly report-back court visits, and then to visits every 2 weeks by Phase 3, if participants showed sustained abstinence.

Of the first 160 drug court program clients who had their cases held for initial sentencing on or after March 1, 2010 to November 8, 2011, 24 were removed from the randomized controlled trial due to ineligibility for the trial or to receiving treatment in residential rehabilitation facilities. The names of the remaining 136 participants were forwarded to the New South Wales (NSW) Bureau of Crime Statistics and Research, and each participant was randomized within blocks to ensure a balanced accrual in the IJS program group and control group. All court officers were blinded to the randomization.

There were 66 drug court clients randomly assigned to the IJS program (treatment group) and 70 drug court clients assigned to the SAU condition (control group). The average age of IJS program participants was 32.2, 84.9 percent were male, and 13.6 percent were from indigenous Australian groups. In terms of seriousness of offense, 37.9 percent of IJS program participants had committed a break, enter, and steal offense; 33.3 percent a theft offense; 12.1 percent a driving offense; and 16.7 percent another offense. Fifteen percent of IJS participants were being treated for use of alcohol, 35.4 percent for amphetamines, 29.2 percent for benzodiazepines, 52.3 percent for cannabis, 15.4 percent for cocaine, and 70.8 percent for heroin. The average age of SAU participants was 32.5, 82.9 percent were male, and 8.6 percent were from indigenous Australian groups. In terms of seriousness of offense, 25.7 percent of SAU participants had committed a break, enter, and steal offense; 40 percent a theft offense; 15.7 percent a driving offense; and 18.6 percent another offense. Seven percent of SAU participants were being treated for use of alcohol, 35.8 percent for amphetamines, 23.2 percent for benzodiazepines, 46.4 percent for cannabis, 8.7 percent for cocaine, and 75.4 percent for heroin. There were no statistically significant differences between IJS and SAU participants on any of these characteristics.

Data on participants? demographic characteristics, urinalysis outcomes, sanctioning, and time in the program was collected from the NSW Drug Court database. Data on initial and final sentences was obtained from manual spreadsheets maintained by the Parramatta Drug Court. Data on prior criminal offenses was collected from a reoffending database maintained by the NSW Bureau of Crime Statistics and Research.

There were four outcome measures for this trial: 1) drug tests, 2) sanctions, 3) progression to Phase 2, and 4) termination. A positive drug test was defined as any test in which the participant tested positive to any drug, admitted any drug use to the court, failed to attend a scheduled drug test, or failed to provide a urine sample at a testing episode. Two separate sanctioning measures were constructed to determine how many sanctions were accrued and served. The first measure counted the number of sanctions (days in custody) accrued per ?free week? on the programs. Free weeks were counted as those weeks when one or more judicial status hearings were listed, while weeks when no judicial status hearings were listed were recorded as missing. The second measure counted the number of sanction days issued to serve during each free week on the programs. Progression to Phase 2 was measured as a categorical outcome: yes or no. Termination was measured as a categorical outcome: not terminated to prison or terminated to prison.

Multilevel logistic regression model analyses were conducted to test whether there was any difference between groups in their odds of returning positive urinalysis tests. A chi-squared test was employed to test whether there was any difference between groups in their likelihood of progressing to Phase 2 of the program. The Kaplan-Meier estimator was used to assess whether there was any difference between groups in the number of days it took participants to be terminated and returned to prison. Cox proportional hazards regressions models were .used to assess whether there was any interaction between supervision, risk, and time on the program. The study authors did not conduct subgroup analyses

These sources were used in the development of the program profile:

These sources were used in the development of the program profile:

Following are CrimeSolutions-rated programs that are related to this practice:

Adult Drug Courts

Drug courts are specialized courts that combine drug treatment with the legal and moral authority of the court in an effort to break the cycle of drug use and drug related crime.

Evidence Ratings for Outcomes

	Crime & Delinquency - Multiple crime/offense types
	Crime & Delinquency - Drug and alcohol offenses
	Drugs & Substance Abuse - Multiple substances

Why might a practice's outcome ratings differ from the ratings of specific programs encompassed by that practice?